AlphaMadera's AlphaVal page computes Novo Nordisk A/S's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag NVO as undervalued, fairly valued, or overvalued.

What is Novo Nordisk A/S's fair value?

Fair value for NVO is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value NVO?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from NVO's most recent reported fundamentals.

NVO - Novo Nordisk A/S

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $45.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Moderate

Trading 26.6% below fair value

Current Price $50.96

Bear Case $59.49 16.7% upside ($59.49 - $50.96) / $50.96 = 16.7% $3.80 × 18x P/E

Fair Value $69.39 36.2% upside ($69.39 - $50.96) / $50.96 = 36.2% $3.80 × 21x P/E

Bull Case $79.31 55.6% upside ($79.31 - $50.96) / $50.96 = 55.6% $3.80 × 24x P/E

Adjust Assumptions

P/E Multiple

21.0x

Adjusted EPS

3.8$

Key Value Driver

Normalized P/E multiple (21x base case)

Implied Market Multiple 13.4x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $45.00 from 39 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $69.39 per share.

Warnings

⚠ The company pays out 99% of its profits as dividends. That leaves little cushion — the dividend could be cut if business slows down.

ℹ Dividend-based valuation: $855.78 (above our primary estimate by 972%). Large gaps may signal the dividend doesn't reflect full earning power.

ℹ Wall Street's average price target is $45.00 (from 39 analysts). Our estimate is 77% above the consensus -- consider that gap carefully.

ℹ Financial statements were converted from DKK into USD using USDDKK at 0.1522 USD per DKK.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples